Table 3

Changes from baseline in ACR core domains at week 16

ACR domain	Infliximab plus methotrexate (n=56)	Methotrexate (n=54)	p Value
Swollen joint count, median change^*	–11.0	–9.0	0.0016
Tender joint count, median change^*	–14.0	–9.5	0.0007
Subject's pain assessment,^† mean change±SD (mm)	–45.8±26.4	–23.1±20.0	<0.0001
Subject's GAD,^† mean change±SD (mm)	–43.0±24.2	–24.1±22.7	<0.0001
Evaluator's GAD,^† mean change±SD (mm)	–47.4±18.3	–30.6±21.6	<0.0001
HAQ–DI, mean change±SD	–0.99±0.72	–0.56±0.72	0.0041
CRP, median change (mg/l)	–12.0	–5.8	0.0026
ESR, median change (s)	–12.0	–8.0	0.0023

↵* Based on raw data.
↵† Using VAS.
ACR, American College of Rheumatology; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GAD, global assessment of disease activity; HAQ–DI, health assessment questionnaire–disability index.